Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TEAD1 | P28347 | 4/20 | 0.39 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22285813 | 1.00 | NOTUM (0.40) | NOTUMLMNATEAD1TEAD3L3MBTL1 | |
| SCHEMBL18616809 | 1.00 | NOTUM (0.40) | NOTUMLMNATEAD1TEAD3L3MBTL1 | |
| SCHEMBL2251284 | 0.89 | ALDH1A1 (0.42) | ALDH1A1TSHRJAK3 | |
| SCHEMBL5121118 | 0.89 | ALDH1A1 (0.42) | ALDH1A1TSHRJAK3 | |
| SCHEMBL18616042 | 0.89 | ALDH1A1 (0.42) | ALDH1A1TSHRJAK3 | |
| SCHEMBL4862871 | 0.88 | LMNA (0.46) | LMNATEAD1TEAD3L3MBTL1MAPT | |
| SCHEMBL4866854 | 0.84 | TET3 (0.35) | LMNATEAD1TEAD3ALDH1A1TSHR | |
| SCHEMBL18585911 | 0.83 | GAA (0.42) | LMNAMAPTALDH1A1 | |
| SCHEMBL18585909 | 0.83 | GAA (0.42) | LMNAMAPTALDH1A1 | |
| SCHEMBL22138093 | 0.80 | HPGD (0.55) | LMNAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844022-B1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI SCIENCE CO LTD (KR) | 2013-08-14 | — | — | EP | claimed |
| JP-2008525522-A | — | — | 2008-07-17 | — | — | JP | claimed |
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | HANMI PHARM CO., LTD (KR) | 2008-01-10 | — | — | US | claimed |
| EP-1844022-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2007-10-17 | — | — | EP | claimed |
| WO-2006071017-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | claimed |
| EP-3684776-B1 | HETEROCYCLYL SUBSTITUTED PYRROLOPYRIDINES THAT ARE INHIBITORS OF THE CDK12 KINASE | UNIV NOTTINGHAM (GB) | 2023-11-01 | — | — | EP | disclosed |
| US-20220281871-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-09-08 | — | — | US | disclosed |
| US-11407767-B2 | Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase | UNIV NOTTINGHAM (GB) | 2022-08-09 | — | — | US | disclosed |
| US-11186576-B2 | Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-11-30 | — | — | US | disclosed |
| US-11186576-B2 | Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-11-30 | — | — | US | disclosed |
| EP-3268000-B1 | PYRAZOLO[1,5-A][1,3,5]TRIAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS CDK INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2021-08-04 | — | — | EP | disclosed |
| EP-3268000-B1 | PYRAZOLO[1,5-A][1,3,5]TRIAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS CDK INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2021-08-04 | — | — | EP | disclosed |
| US-20180057497-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-03-01 | — | — | US | disclosed |
| EP-3268000-A2 | PYRAZOLO[1,5-A][1,3,5]TRIAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS CDK INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016142855-A2 | PYRAZOLO[1,5-A][1,3,5]TRIAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS CDK INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-09-15 | — | — | WO | disclosed |
| WO-2016142855-A2 | PYRAZOLO[1,5-A][1,3,5]TRIAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS CDK INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-09-15 | — | — | WO | disclosed |
| EP-1844022-B1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI SCIENCE CO LTD (KR) | 2013-08-14 | — | — | EP | disclosed |
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | HANMI PHARM CO., LTD (KR) | 2008-01-10 | — | — | US | disclosed |
| EP-1844022-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006071017-A1 | QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF | HANMI PHARM. CO., LTD. (KR) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057497-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | CDK15, CDK1, CDK19 | NOTUM 4565/4885LMNA 1385/4885TEAD1 1126/4885 |
| US-20080009509-A1 | Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof | MKI67, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | NOTUM 917/4885LMNA 3026/4885TEAD1 410/4885 |
| US-11407767-B2 | Heterocyclyl substituted pyrrolopyridines that are inhibitors of the CDK12 kinase | CDK1, CDK11A, CDK12 | NOTUM 4320/4885LMNA 491/4885TEAD1 2021/4885 |
| US-20220281871-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | CDK15, CDK13, CDK1 | NOTUM 4435/4885LMNA 1353/4885TEAD1 1641/4885 |
| US-11186576-B2 | Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors | CDK15, CDK1, CDK19 | NOTUM 4565/4885LMNA 1385/4885TEAD1 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.